Protein painting identifies therapeutic targets at protein-protein interfaces
Protein painting identifies therapeutic targets at protein-protein interfaces
批准号:
9392299
负责人:
Lance Allen Liotta
金额:
$9.45万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2016
资助国家:
美国
项目状态:
已结题
起止时间:
2016-09-01 至 2019-08-31
关键词:
AffinityAmino AcidsBindingBiological AssayCategoriesCell CommunicationCell Surface ReceptorsCell surfaceCellsChemicalsChemistryComplexConsensusCrystallizationCrystallographyDataDeuteriumDissociationDyesFaceFolliculinHot SpotHydrogenImmuneImmune Cell SuppressionImmunotherapyIn VitroLigandsMalignant NeoplasmsMapsMethodsMolecularMolecular ConformationMonoclonal AntibodiesOncogenesPDCD1LG1 genePaintPathway interactionsPeptide HydrolasesPeptide antibodiesPeptidesProductionProtein Binding DomainProtein RegionProteinsProteolysisProtocols documentationReceptor CellReceptor SignalingResolutionSideSignal TransductionSignaling ProteinSiteSolventsSpecificityStructureSuppressor GenesSurfaceTechnologyTherapeuticTimeTrypsinTumor Suppressor ProteinsValidationWestern Blottingaryl hydrocarbonschymotrypsincrosslinkdrug candidatemonoclonal antibody productionneoplastic cellnew technologynext generationnovelpointed proteinprotein complexprotein protein interactionsmall moleculesurface coatingsynthetic peptidetherapeutic targettumor
中文摘要
点击翻译按钮获取中文摘要
英文摘要
The next generation of molecular cancer therapeutics will target pivotal protein-protein interaction interfaces
participating in immune cell receptor signaling, oncogenes, and suppressor genes. We will implement a truly
transformative, wholly novel, technology “protein painting” for the rapid direct sequencing of hidden native
protein-protein interaction hot spots, that was originated under NCI R21 IMAT CA177535. Our technology
employs previously unexplored small molecule (12 Å) aryl hydrocarbon dyes or “paints” to cut out, and MS
sequence, only the hidden unmodified contact interfaces between two or more interacting native proteins.
Protein painting employs a completely new principle that yields a much higher specificity and three times
higher number of positive hits compared to chemical footprinting methods. Paint chemistries have extremely
high affinities (rapid on-rates, and very slow off-rates that are ten to 100 times higher than most protein-protein
interactions). When mixed with a native pre-formed protein complex for only 5 minutes, the paints non-
covalently coat all external sites on the protein without altering the 3D conformation of the complex, but cannot
gain access to the solvent inaccessible hidden protein-protein interaction domains. Each paint molecule spans
3 amino acids or less, and has high affinity for protease cleavage consensus sites. Following painting, the
unbound paints are washed away and the proteins are dissociated. This leaves the paint molecules coating
surfaces not participating in the interface. Following dissociation, the proteins are linearized, digested with
proteolytic enzymes, and sequenced by MS. The paint molecules remain non-covalently bound after the
proteins are denatured. Proteolytic enzymes such as trypsin will not cleave the regions of the protein that are
“painted”. Following proteolysis, therefore, peptides emerging from MS will exclusively be generated from the
unmodified opposing points where the proteins were in intimate contact. All of the original R21 Aims and
Milestones were fully met. A very high correlation (p<0.0003) was found between protein painting and the
contact points predicted by crystal structure, with a 97% specificity for true positive hot spots. We discovered
evolutionarily conserved 3-way hotspots and verified their functional importance by creating peptides and
mAbs that block the interaction and extinguish signaling. Under Aim1, we will discover novel hotspot
sequences of broad therapeutic relevance for interacting protein complexes of three types: 1) cell surface
receptors (PD1/PDL-1,PDL-2) involved in tumor immune cell suppression , 2) Hippo cancer suppressor
pathway proteins, and 3) the recently elucidated oncogene Folliculin.Under Aim 2 we will validate the functional
(drug candidate) importance of the interaction hotspots we discover, by creating peptides and monoclonal
antibodies that bind to the opposing hotspot faces of the interacting proteins. We will verify that these ligands
will suppress protein complex formation. For the PD1/PDL-1,PDL-2 cell surface complexes, we will extend
protein painting, for the first time, to MS sequence cell-cell interaction contact points in cultured live cells.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Targeting Rab6-km23-1-mediated compartmentalized trafficking as a novel therapeutic approach to Alzheimers Disease
-
批准号:9756263
-
项目类别:
-
资助金额:$19.14万
-
财政年份:2018
-
负责人:Lance Allen Liotta
-
依托单位:
Protein painting identifies therapeutic targets at protein-protein interfaces
-
批准号:9338200
-
项目类别:
-
资助金额:$34.82万
-
财政年份:2016
-
负责人:Lance Allen Liotta
-
依托单位:
Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation
-
批准号:9085212
-
项目类别:
-
资助金额:$56.88万
-
财政年份:2015
-
负责人:Lance Allen Liotta
-
依托单位:
Probes to target the 3-way hotspot of IL1RacP to abolish aberrant interleukin inflammation
-
批准号:8944833
-
项目类别:
-
资助金额:$59.52万
-
财政年份:2015
-
负责人:Lance Allen Liotta
-
依托单位:
Protein Painting reveals hidden protein-protein interaction domains
-
批准号:8728792
-
项目类别:
-
资助金额:$23.73万
-
财政年份:2013
-
负责人:Lance Allen Liotta
-
依托单位:
Protein Painting reveals hidden protein-protein interaction domains
-
批准号:8547427
-
项目类别:
-
资助金额:$24.47万
-
财政年份:2013
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8548317
-
项目类别:
-
资助金额:$34.65万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8433072
-
项目类别:
-
资助金额:$38.04万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotrap technology for one step preservation and amplification of cancer biomark
-
批准号:8723137
-
项目类别:
-
资助金额:$35.76万
-
财政年份:2012
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8311650
-
项目类别:
-
资助金额:$30.95万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8504815
-
项目类别:
-
资助金额:$28.52万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
A non-invasive nanotechnology-based skin patch for multiplexed diagnostics
-
批准号:8265831
-
项目类别:
-
资助金额:$19.64万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Implementation of phosphoprotein preservation technology for cancer biospecimens
-
批准号:8079819
-
项目类别:
-
资助金额:$32.74万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
A non-invasive nanotechnology-based skin patch for multiplexed diagnostics
-
批准号:8092239
-
项目类别:
-
资助金额:$16.37万
-
财政年份:2011
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7847757
-
项目类别:
-
资助金额:$1.06万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers i
-
批准号:7586530
-
项目类别:
-
资助金额:$14.92万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Nanotechnology for One Step Concentration and Preservation of Labile Biomarkers i
-
批准号:7935029
-
项目类别:
-
资助金额:$20.04万
-
财政年份:2009
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7680019
-
项目类别:
-
资助金额:$19.28万
-
财政年份:2008
-
负责人:Lance Allen Liotta
-
依托单位:
Surrogate and Sentinal Technologies to Monitor Stability of Cancer Phosphoprotein
-
批准号:7846929
-
项目类别:
-
资助金额:$1.08万
-
财政年份:2008
-
负责人:Lance Allen Liotta
-
依托单位:
Phosphorylated signal pathway proteins: A new class of vitreous biomarkers for op
-
批准号:7451923
-
项目类别:
-
资助金额:$17.27万
-
财政年份:2008
-
负责人:Lance Allen Liotta
-
依托单位:
海外基金